Jpmorgan Chase & CO Aravive, Inc. Transaction History

Jpmorgan Chase & CO

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 12, 2024	BUY	$0.11 - $0.22 $2 - $5	27 Added 49.09%	82 $0
Q3 2023 Nov 14, 2023	BUY	$0.11 - $1.76 $3 - $63	36 Added 189.47%	55 $0
Q2 2022 Aug 11, 2022	SELL	$0.93 - $1.9 $64 - $131	-69 Reduced 78.41%	19 $0
Q1 2022 May 11, 2022	BUY	$1.85 - $2.75 $127 - $189	69 Added 363.16%	88 $0
Q4 2021 Feb 10, 2022	SELL	$2.19 - $4.07 $54,257 - $100,834	-24,775 Reduced 99.92%	19 $0
Q3 2021 Nov 12, 2021	BUY	$3.67 - $5.8 $90,993 - $143,805	24,794 New	24,794 $92,000

28.1K

Ticker ARAV
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 30,518,300
Description
Aravive, Inc., a clinical-stage biopharmaceutical company, develops treatments for life-threatening diseases, including cancer and fibrosis in the United States. Its lead product candidate is batiraxcept, an ultrahigh-affinity, decoy protein that targets the GAS6-AXL signaling pathway, which is in Phase III clinical trial for the treatment of pl...

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

Stay updated on Jpmorgan Chase & CO with notifications on news.